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Treatment with recombinant human erythropoietin increases
antibody titers after hepatitis B vaccination in dialysis patients
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Renal Unit, Akademisch Ziekenhuis, Vrije Universiteit Brussel, Brussels, Belgium
Treatment with recombinant human erythropoietin increases antibody
titers after hepatitis B vaccination in dialysis patients. The effect of
recombinant human erythropoietiu (rHuEPO) on the immune system of
hemodialysis patients has been studied by evaluating their response to
hepatitis B (HB) vaccination. Fifty hemodialysis patients were given
four doses of 20 sg recombinant DNA hepatitis B vaccine (SKF) at an
interval of 0, 1, 2 and 6 months. Thirty-seven patients could be
evaluated at one year. Twelve of 15 (80%) of the rHuEPO treated
patients and 12 of 22 (54%) of non-rHuEPO treated dialysis patients
developed anti-HB antibodies. At the time of maximum immune
response (8 months), the geometric mean anti-HB titers (mIU/ml
sEM) of responders and all patients were five times (224.0 5.9 vs. 41.7
1.5, P < 0.001), and eight times (57.6 8.7 vs. 6.7 1.8, P < 0.05),
respectively, higher in rHuEPO treated patients than in patients not
receiving the drug. High antibody response (>100 mIU/ml) prevailed in
the group of rHuEPO treated patients and was associated with a high
helper/suppressor ratio. Discriminant multivariate analysis (P = 0.038)
revealed the influence of treatment with rHuEPO (40%) and helper!
suppressor ratio (31%) on antibody concentration, while age, gender,
duration of dialysis and previous blood transfusions were similar in both
patient groups. Although changes in lymphocyte subsets observed in
rHuEPO treated patients may be the result of a reduced administration
of blood transfusions, immune reactivity seems also to be directly
affected by the drug.
Patients undergoing regular hemodialysis exhibit an impair-
ment of their immune potential that mainly involves T cell-
mediated immune responses [1—3]. Increased susceptibility to
infections [4, 5], cutaneous anergy [6], prolonged allograft
survival [7—8] and decreased antibody response to thymus-
dependent antigens like hepatitis B vaccine [9—11] are manifes-
tations of their defect in immunological competence. These
immunologic alterations have been ascribed to: (i) a decrease in
the absolute number of circulating helper T lymphocytes [12—
14]; (ii) the presence of an abnormal immunoregulation medi-
ated by regulatory T lymphocytes, monocytes or soluble serum
factors [15—21]; (iii) the existence of abnormally high propor-
tions of circulating T cells presenting phenotypic and functional
signs of preactivation [22—24].
Since the availability of recombinant human erythropoietin
(rHuEPO), it has been possible to avoid or at least reduce the
number of blood transfusions in most dialysis patients. This
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subject is of special interest since a previous study on the
immune system of hemodialyzed adults demonstrated that
changes in T lymphocyte subsets are accentuated by antecedent
blood transfusions [14].
Pfaffi et al [25] observed phenotypic changes in the lympho-
cyte subpopulations after 18 weeks of therapy with rHuEPO.
They studied 15 hemodialysis patients and found a significant
decrease in absolute T cell numbers which was more pro-
nounced in the suppressor cell subpopulation than in the helper
cell subpopulation, resulting in a significant increase in the
helper/suppressor cell ratio. The biological significance of these
changes remains unclear. Recently, Grimm et a! [26] reported
that in highly sensitized adolescents on dialysis, rHuEPO
treatment and subsequent transfusion avoidance caused a de-
crease in anti-HLA sensitization. These observations suggest
that rHuEPO administration may affect both the cellular and
humoral components of the immune system, and prompted us
to determine whether or not rHuEPO treatment affects the
outcome of hepatitis B vaccination. Our analysis indicates
similar seroconversion rates but higher antibody titers in
rHuEPO treated patients as compared to uremic controls.
Methods
Patients
Fifty stable hemodialysis patients (27 men, 23 women; mean
age 58 years; range 34 to 83 years), negative for HBSAG,
anti-HB and anti-HB were vaccinated with a hepatitis B
vaccine. Patients were dialyzed three times a week for four
hours using capillary dialyzers with a mean surface area of 1.0
m2 (0.8 to 1.4 m2). The mean duration of dialysis was 31 months
(range 6 to 122). Protein intake averaged 1 g/kg body weight.
Serum phosphate was controlled by diet, calcium carbonate 2 to
4 g daily, and if necessary with additional aluminium hydroxide
(maximum dose 3 g/day). Blood pressure was controlled by
sodium and fluid restriction. In some patients antihypertensive
drugs were also associated. The majority of patients received
calcitriol (RocaltroiR), 0.25 pg/day. Four patients were ex-
cluded from statistical analysis because they were lost for
follow-up before the third month after the start of vaccination.
Of the remaining 46 patients, 17 received rHuEPO (rHuEPO
group) for transfusion-dependent anemia while 29 did not
(rHuEPO) and constituted the uremic control group. In the
rHuEPO treated group a mean dose of 81 U/kg rHuEPO (range
41 to 135 U/kg) was administered intravenously thrice weekly
during a mean period of 7.5 months (range 2 to 26 months). No
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Table 1. Characteristics of patients
Controls
(N=29)
rHuEPO
(N= 17)
Age, years
Mean SD 60.3 10.2 55.3 11.1
Range 40—83 34—70
Sex, N(%)
Men 16 (55) 9 (53)
Women 13 (45) 8 (47)
Body mass index, kg/rn2
Mean SD 24.8 3.9 23.8 3.7
Range 18—38 16—30
Underlying kidney disease, N (%)
Polycystic kidney disease 8 (28) 2 (12)
Diabetic nephropathy 3 (10) 2 (12)
Glomerulonephritis 6 (21) 3 (18)
Malignant nephrosclerosis 9 (31) 6 (35)
Interstitial nephropathy 3 (10) 4 (23)
Duration of dialysis, months
Mean SD 31.5 30.6 30.8 29.8
Range 6—122 6—120
Dialysis membrane, N (%)
Cuprophan 5(18) 2(12)
Cellulose acetate 24 (82) 15 (88)
Transfusion, units (mean SD)
Before vaccination 8.4 9.1 16.3 13.la
During vaccination 3.8 6.5 1.2 4•9a
a P < 0.05 as compared to controls
patient received any drug known to have an effect on lympho-
cyte number or function. The clinical characteristics of both
patient groups are presented in Table 1. A careful review of the
dialysis records, charts and blood bank records was done for all
patients to ascertain the amount of blood received. Metabolic
data of rHuEPO treated patients and uremic controls are listed
in Table 3.
Vaccination schedule
A dose of 20 j.tg of the recombinant DNA hepatitis B vaccine
(Engerix BR, Smith Kline Biologicals, Belgium) was adminis-
tered in the deltoid muscle after dialysis. Vaccination was
conducted with four doses given in rapid succession at 0, 1, 2
and 6 months.
Laboratory procedures
Serum urea and creatinine were measured on a Kodak
Ektachem 700 instrument (Rochester, New York, USA). Serum
albumin was determined by electrophoresis on an Olympus
Hite System 200 (Germany). Serum zinc concentration was
determined by atomic absorption spectrophotometry (Instru-
mentation Laboratory Spectrophotometer 457, Andover, Mas-
sachusetts, USA). Serum ferritin was assayed by immunoradi-
ometric assay (QuantimmunR Ferritin IRMA, Blo-Rad,
Richmond, California, USA). Differential blood counts were
obtained on a Technicon Hi (Technicon Instruments, Piscat-
away, New Jersey, USA). All blood samples were taken 72
hours after the last dialysis. Samples for anti-HB antibodies
were taken before and after vaccination at intervals of 0, 1, 2, 3,
6, 8 and 12 months. Antibody titers were measured by radio-
immunoassay (AUSABR, Abbott Laboratories, Chicago, Illi-
nois, USA), expressed as mIU/ml and divided into three
groups: 1 to 10 mIU/ml (low responders, nonprotective); 11 to
100 mIU/ml (medium responders), and over 100 mIU/ml (high
responders). The geometric mean titers (GMT) of anti-HB
were calculated for responders only and for all patients in
rHuEPO treated and uremic control groups at the time stated.
Quantitation of lymphocyte populations
Peripheral blood mononuclear cells (PBM) were isolated by
centrifugation at 500 x g during 20 minutes on a Ficoll-
Metrizoate gradient (LymphoprepTM, Nycomed Pharma, Oslo,
Norway) as described by Bojum [27]. PBM were recovered at
the interface and washed twice in phosphate buffered saline
containing 1% bovine serum albumin (PBS). Indirect immuno-
fluorescence was performed as previously described [28].
Briefly, 500,000 cells were incubated for 30 minutes at room
temperature with appropriate dilutions of the monoclonal anti-
bodies Leu4, Leu3a, Leu2, Leu32 and Leu1 1b (Beckton-Dickin-
son, California, USA) that respectively recognize total human T
cells (CD3), helper/inducer (CD4) and cytotoxic/suppressor T
cells (CD8), total human B-cells (CD19) and natural killer cells
(CD16). After two washes with PBS, the cells were labeled for
30 minutes at room temperature with fluorescein (FITC)-conju-
gated goat anti-mouse IgG antiserum (Dakopatts, Glostrup,
Denmark). Following washing and resuspension in PBS con-
taining 0.05% sodium azide, the cells were analyzed by fluores-
cent-activated cell sorter (FAC Scan, Beckton-Dickinson). Ab-
solute numbers of each separate T cell subset were calculated
as the product of the total white cell count, percent lympho-
cytes and the percent positive cells determined by flow cytom-
etry.
All blood samples were taken at the same time of the day
before dialysis was started, two weeks prior to vaccination and
on the day of the administration of the first dose of vaccine.
Since there was no intrapatient variation between these two
subsequent lymphocyte determinations, only the latter were
considered for calculation. Control blood samples were ob-
tained from 42 healthy blood donors matched for age and sex.
Statistical methods
The Mann-Whitney U, unpaired t, chi square or Fisher's
exact and Spearman correlation tests were used for the univari-
ate statistical procedures. Stepwise linear regression analysis
by forward selection with pair switching was used for multiple
regression analysis. Discriminant multivariate analysis with
stepwise procedure was chosen for the analytical part and
RAO's V used as the multivariate index of separation. The
relative discriminating part of each variable was calculated by
the standard canonical discriminant coefficients and expressed
in percent [29]. All calculations were performed on a IBM
computer (SPSS/PC + program).
Results
Follow-up
Thirteen patients were lost during the observation period of
12 months: seven died from intercurrent disease and six others
underwent renal transplantation. Forty-six and 42 patients were
considered in the evaluation at month six and month eight,
respectively. At one year, 37 patients were still continuing the
trial.
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Table 2. Geometric mean anti-HB, titers (mIU/ml SEM) in dialysis patients treated with rHuEPO, uremic controls and entire population at
intervals after quadruple vaccination
Controls rHuEPO Entire population
R A R AMonths R A
3 3.7 0.1 1.6 0.5 14.9 l.oa 3.6 12b 6.8 0.9 2.1 0.5
(10) (29) (8) (17) (18) (46)
6 10.7 0.9 3.2 0.8 18.0 l.sa 7.8 17b 13.6 0.8 4.4 0.8
(14) (29) (12) (17) (26) (46)
8 41.7 1.5 6.7 1.8 224.0 59 576 87b 93.5 2.5 14.8 3.0
(13) (26) (12) (16) (25) (42)
12 15.1 1.3 4.4 1.3 71.3 6.0a 30.2 6.5l 33.! 2,4 9.5 2.2
(12) (22) (12) (15) (24) (37)
Abbreviations are: R, responders only; A, all patients. Values in parentheses denote the number of patients tested
a P < 0.001, as compared to controlsb P < 0.02, as compared to controls
Seroconversion
Overall seroconversion was 39% at three months post-vacci-
nation, 56% at six months, 59% at eight months and 65% at 12
months. In uremic controls, anti-HB was present after three
months in 34%, after six months in 48%, after eight months in
50% and after 12 months in 54%. The conversion rates of
patients receiving rHuEPO were 47, 70, 71 and 80%, respec-
tively (P = 0.11, NS).
Antibody titers
The geometric mean anti-HB titers of the hemodialysis
patients at different time intervals after quadruple vaccination
are shown in Table 2 for the entire study population, rHuEPO
treated patients and uremic controls, both for responders only
and for all patients in each group. At month eight, the maximum
geometric mean titers (mIU/ml SEM) in rHuEPO treated
patients and uremic controls, respectively, were 224.0 5.9
versus 41.7 1.5 for responders only (P <0.001) and 57.6 8.7
versus 6.7 1.8 for all patients (P < 0.05). Figure 1 depicts the
time courses of geometric mean anti-HB titers of serocon-
verted patients after quadruple vaccination. The fourth vacci-
nation led to an abrupt rise of anti-HB, titers, culminating two
months later, that is, in month eight. By month 12 a decline in
anti-HB, titers occurred. A similar pattern was observed for
responders of the entire population, rHuEPO treated patients
and uremic controls.
The cumulated proportions of medium (anti-HB titer  10
mIU/ml) and high (anti-HB titer  100 mIU/ml) responders at
different time intervals after vaccination were analyzed accord-
ing to treatment with rHuEPO as illustrated in Figure 2. The
proportion of seroconverted patients with anti-HB titers ex-
ceeding 10 mIU/ml was higher in patients receiving rHuEPO
than in those not receiving the drug three months after the start
of vaccination (62% vs. 20%, P < 0.05) but not later on. In the
rHuEPO treated group, the cumulative proportion of serocon-
verted patients with anti-HB titers exceeding 100 mIU/ml
increased from 13% (month 3) to a maximum of 58% (month 8)
and remained stable to the 12th month. In patients not receiving
rHuEPO, high antibody response did not occur until month
eight and was observed in only 20% of the patients (P < 0.05).
By month 12, all these patients evidenced a drop in antibody
titer below 100 mIU/ml (P <0.02).
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Fig. 1. Immunization rates (%) and geometric mean anti-HB titers
(GMT, miUlmI) of seroconverted dialysis patients after quadruple
vaccination for all patients (- -A - -), r-HuEPO treated patients(rHuEPOt •) and uremic controls (rHuEPO, ..) (°NS; * D
0.001, rHuEPO4' compared to rHuEPO).
The distribution of the anti-HB titers attained by the sero-
converted patients at the moment of maximum antibody re-
sponse in month eight is shown in Figure 3. In patients not
receiving rHuEPO, the majority of immunized individuals were
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rHuEPO treated patients and uremic controls was 23.8 and 24.8
kg/rn2, respectively (NS). Patients with polycystic kidney dis-
ease tended to be more frequently represented in the control
group and patients with interstitial disease in the rHuEPO
treated group. Mean length of time on maintenance dialysis of
rHuEPO treated patients and controls was 30.8 and 31.5
months, respectively (NS). A total of 88% of rHuEPO receiving
patients and 82% of controls were dialyzed on cellulose acetate
membranes (NS).
Mean number of transfusions per patient administered before
vaccination was 16.3 units in rHuEPO treated and 8.4 units in
untreated patients (P < 0.05). During the 12 months study
period, transfusion needs were 1.2 and 3.8 units per patient in
rHuEPO treated patients and uremic controls, respectively (P
<0.05).
rHuEPO — rHuEPO +
Fig. 3. Seroconversion rates (%) at the 8th month of the study in the
control group (rHuEPO, N = 29) and the rHuEPO treated group (N
= 17) as well as anti-HB titers attained by the seroconverted patients.
** P < 0.02, high responders, rHuEPO compared to rHuEPO.
Symbols are: () < 10 mIU/ml anti-HBAG; (0) 10—100 mIU/ml
anti-HB5AG; (0)> 100 mIU/ml anti-HBAG.
medium responders, whereas in the rHuEPO treated group high
responders predominated (P < 0.02).
Factors influencing the response to hepatitis B vaccination
Patient demographics (Table 1). Mean age of rHuEPO
treated patients and uremic controls was 55.3 and 60.3 years,
respectively (NS). Both patient groups were constituted of
equal numbers of men and women. Mean body mass index of
Prevaccination biochemistry and hematology
Predialysis blood urea nitrogen, serum creatinine, albumin,
zinc and hemoglobin concentrations were similar in both patient
groups (Table 3). Mean serum ferritin was 444 pg/liter in
patients receiving rHuEPO and 267 pg/liter in uremic controls
(P < 0.02).
Prevaccination immune parameters. Differential blood
counts and lymphocyte subpopulations of healthy subjects,
uremic controls not receiving rHuEPO and rHuEPO treated
patients, are summarized in Table 4.
Although the total white cell count was not significantly
changed in dialysis patients as compared with healthy subjects,
patients showed an increase in polymorphs and a decrease in
lymphocyte counts (P < 0.001). The proportion of helper/
inducer T cells (Leu3a) was increased in the uremic population
(P < 0.05) while the representation of suppressor/cytotoxic T
cells (Leu2) was decreased (P < 0.05). As a consequence of
124 Sennesael et al: rHuEPO and anti-HB titers
1.0
3
Time, months
0.8
0.6
0.4
0.2
0.0
100
80
60
40
20
6 8 12
Fig. 2. Fractional distribution of medium
(anti-HB,> 10 miUlmi) and high (anti-HB5>
100 mIU/ml) responders at different time
intervals after vaccination according to
treatment with rHuEPO. Symbols are: (0)>
10 rHuEPO; (0)> 100 rHuEPO; (a)> 10
rHuEPO;(0)>JOOrHuEPO. *D<•5,
medium responders month 3, rHuEPO
compared to rHuEPO, ** P < 0.05, P <
0.02, high responders month 8 and 12,
rHuEPO compared to rHuEPO.
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Table 3. Metabolic findings in hemodialysis patients (mean SEM)
Controls
(N=29)
rHuEPO
(N= 17)
Biochemistry
Blood urea nitrogen mmol//iter 22.2 1.2 26.5 1.5
Creatinine i.unol/liier 986.0 58.0 933.0 52.0
Albumin glliter 35.0 2.0 36.0 3.0
Zinc uno1Iliter 8.0 0.2 8.4 0.3
Hematology
Hemoglobin gIdi 9.0 0.4 9.6 0.3
Ferritin g/1iter 267.0 69.0 444.0 96.Oa
a P < 0.02 as compared to controls
Table 4. Prevaccination immune parameters in hemodialysis patients
and healthy subjects (mean 5EM)
Healthy
subjects
Hemodialysis patients
Controls rHuEPO
Leucocytes /mm3 5960.0 360.0 6840.0 350.0 5220.0 400.0
Polymorphs % 50.9 1.8 65.0 l,4c 62.2 2.l
/mm3 3063.0 260.0 4491.0 226.Oe 3507.0 3l7.O''
Lymphocytes, % 37,2 1.8 21.8 1.0c 21.3 16d
/mm3 2186.0 131.0 1460.0 85.0c 82.0 98.OaC
T cells % 75.5 2.5 76.2 2.1 75.5 2.8
(Leu4/CD3) /mm3
Helper cells %
1654.0 128.0
43.0 2.1
1038.0 67,0c
52.6 2.le
730.0 65.0
54.0 31d
(Leu3a/CD4) /mm3
Suppressor cells %
928.0 51.0
33.8 2.7
714.0 48.Oe
29.2 1.5
509.0 42.O
26.8 2,6d
(Leu2/CD8) /mm3
Helper/suppressor
760.0 106.0
1.4 0.2
393.0 27.0c
2.0
272.0 48.Oa.c
2.6 0.5'
B cells % 6.8 0.7 7.2 0.8 8.0 1.3
(Leu12/CD19) /mm3 151.0 18.0 98.0 14.Oe 75.0 l3.Oe
NK cells % 10.6 1.4 15.1 1.8 16.0 2.4
(LeuIIb/CD16) /mm3 227.0 31.0 205.0 24.0 162.0 36.0
a P < 0.005 as compared to controls
b P < 0.05 as compared to controls
P < 0.001 as compared to healthy subjectsd P < 0.05 as compared to healthy subjects
P < 0.005 as compared to healthy subjects
these changes, the helper/suppressor ratio was increased (P <
0.05). The percentage of B cells (Leu12) and NK cells (Leu11b)
was not different from the levels found in the healthy popula-
tion. When absolute numbers were compared, a decrease was
seen in total lymphocyte counts and in the numbers of T cells
(Leu4), helper (Leu3a) and suppressor (Leu2) subsets (all P <
0.001) and B cells (Leu12) (P < 0.005), whereas absolute
numbers of NK cells (Leu1 1b) were not different from healthy
subjects.
Compared to uremic controls, dialysis patients receiving
rHuEPO had lower peripheral blood leucocyte counts (P <
0.005) without a shift in differential blood count or change in
relative proportions of lymphocyte subsets. rHuEPO treated
dialysis patients had a decrease in total number of lymphocytes
and T cells (P < 0.005). The decrease in the suppressor cell
subset was more pronounced than in the helper cell subset (P <
0.005), thus tending to increase the helper/suppressor cell ratio.
B lymphocytes (Leu12) were equally depressed in rHuEPO
treated and untreated patients. Absolute numbers of NK-cells
(Leu1 1b) were not different from uremic controls.
A correlation was found between the number of prevaccina-
Table 5. Age, rHuEPO treatment, blood transfusion and
prevaccination immune parameters in patients with no and high
antibody response to HBSAG (mean 5EM)
High
Nonresponders(N=l7) responders(N=lO)
Fraction rHuEPO 0.2 0,7b
Age, years 62.1 2.5 56.2 2.4
Leucocytes /mm3 6070.0 380.0 5480.0 610.0
Polymorphs % 65.0 1.1 67.1 2.9
/mm3 3970.0 292.0 3720.0 482.0
Lymphocytes % 23.4 1.4 20.0 1.7
/mm3 1406.0 110.0 1051.0 l12,Oa
T cells % 71.6 2.8 76.8 2.8
(Leu4/CD3) /mm3
Helper cells %
924.0 85.0
45.6 2.7
763.0 110.0
57.2 3,1b
(Leu3a/CD4) /mm3 589.0 59.0 554.0 71.0
Suppressor cells % 32.3 2.2 22.6 2.6a
(Leu2/CD8) /mm3 424.0 50.0 228.0 42,0c
Helper/suppressor 1.6 0.2 3.3 0.8c
B cells % 7.8 1.0 7.8 1.7
(Leu12/CD19) /mm3 100.0 14.0 69.0 12.0
NK cells % 19.3 2.7 12.3 2.2
(LeuIlb/CD16) /mm3 248.0 39.0 110.0 20.0
Transfusion, units
before vaccination 16.3 7.4 8.4 2.4
during vaccination 2.9 0.8 0.3 o.la
a p < 0.05 as compared to nonrespondersb P < 0.02 as compared to nonresponders
P < 0.01 as compared to nonresponders
tion blood transfusions and the decrease in the percent repre-
sentation and absolute numbers of total T cells (—0.3869, P <
0.05) and the absolute number of T helper cells (—0.4486, P <
0.01). Since age, gender, duration of dialysis and blood trans-
fusion may affect peripheral blood leucocyte count and lympho-
cyte subsets, multiple regression analysis was used to examine
the interactions of these variables. A significant correlation was
found between the decrease in percent representation and
absolute number of I helper cells (P < 0.05) and the number of
prevaccination blood transfusions.
Finally, age, gender, treatment with rHuEPO, blood transfu-
sion history and prevaccination immune parameters were eval-
uated for their influence on the ability to respond to hepatitis B
vaccination. Ten patients with high anti-HB titers at month 8
were compared with 17 patients not responding to hepatitis B
vaccination (Table 5). No significant difference could be found
in age, total and differential blood leucocyte count, percentage
and absolute numbers of T (Leu4), B (Leu1 2)and NK (Leu1 1b)
cells. High responders had lower absolute lymphocyte counts
than nonresponders (P < 0.02). Their proportion of helper
(Leu3a) cells was higher and their proportion and absolute
number of suppressor (Leu2) cells lower (P < 0.05 and P <
0.01, respectively), resulting in an increase in the helper!
suppressor cell ratio (P < 0.01). The fraction of patients
receiving rHuEPO was 0.7 in the high responder group com-
pared to 0.2 in the nonresponder group (P < 0.02). The total
number of blood transfusions before vaccination tended to be
higher in the nonresponder group than in the high responder
group (P = 0.56, NS). On the contrary, during the 12-month
observation period after the first injection of vaccine, nonre-
sponders continued to require more transfusion than high
responders (P <0.05). Absolute number of T lymphocytes and
126 Sennesael et a!: rHuEPO and anti-HB titers
T-helper cells correlated negatively with the number of trans-
fusions in the high responder group only (—0.5618, P < 0.05 and
—0.6524, P < 0.02, respectively). Mean serum ferritin was
284.0 72.0 jsg/liter in nonresponders and 445.7 145.0
g/1iter in high responders (P = 0.22, NS). Discriminant multi-
variate analysis (P =0.038) revealed a strong influence of
rHuEPO treatment (40%) and helper/suppressor ratio (31%) on
the ability to respond to hepatitis B vaccination, whereas age,
gender, duration of dialysis, blood urea nitrogen, serum creat-
mine, absolute number of B cells (Leu12) and the total number
of blood transfusions all contributed for less than 10%.
Discussion
Anti-HB antibodies developed in 65% of the dialysis patients
after quadruple vaccination. A comparable rate of immuniza-
tion was reported in other investigations using another vaccine
and vaccination schedule [9—li, 30—32]. In our study, a higher
percentage of rHuEPO treated dialysis patients developed
anti-HB antibodies than control dialysis patients. However,
this difference was not statistically significant. Several ap-
proaches were used to evaluate the concentration of anti-HB
after quadruple vaccination. A first approach was to calculate
geometric mean anti-HB titers of responders only and of all
patients at different time intervals following vaccination. A
second approach was to determine the relative proportion of
medium and high antibody response at different time intervals
after vaccination. Finally, the distribution of the antibody titers
attained by the seroconverted vaccinees at the moment of
maximum immune response was considered. Our analysis
consistently demonstrated higher anti-HB titers in patients
receiving rHuEPO compared to uremic controls receiving the
same dose of antigen. Although these results need confirmation,
we emphasize that nonhomogeneity of the study groups can be
excluded. The composition of both groups was virtually iden-
tical except for a higher percentage of patients with interstitial
nephropathy in the rHuEPO treated group and a higher per-
centage of patients with renal polycystic disease in the control
group. This difference was not statistically significant, however.
Besides, previous studies [10, 24] could not demonstrate a
significant influence of primary renal disease on the outcome of
hepatitis B vaccination. Blood urea nitrogen, serum creatinine,
zinc and albumin as well as hemoglobin concentration were
comparable in both groups. In the rHuEPO treated patients,
however, the mean serum ferritin level was significantly higher
as compared to control patients, corresponding to their prior
transfusion history. Should this exert any effect on anti-HB
titer, a negative influence would seem to be much more prob-
able than a positive one, since excess iron, at levels comparable
to those found in the serum of patients with iron overload, has
been shown to impede the generation of antigen specific im-
mune responses [33, 34].
Interesting differences were evidenced in the prevaccination
immune parameters of rHuEPO treated and untreated patients.
In agreement with previous studies [12—14, 35], we observed a
relative and absolute depletion of lymphocytes in the dialysis
population with absolute decrease in both B and T lymphocytes
and their subsets as well, with the exception of the NK cell
subset. The dialyzed patients, compared to healthy subjects had
higher percentage of helper cells and lower percentage of
suppressor cells, resulting in a significantly higher helper/
suppressor ratio. Compared to dialyzed controls, rHuEPO
treated patients were even more lymphopenic at the start of
vaccination. Their B lymphocytes were equally depressed, but
in the T cell population the depletion of suppressor T cells was
more pronounced, increasing the helper/suppressor ratio still
further. The highest helper/suppressor ratio was recorded in the
high responder group where rHuEPO treated individuals pre-
vailed. The correlation of antibody response with helper/sup-
pressor ratio is consistent with the well known interplay be-
tween inducer and suppressor influences of T cells upon the B
cell proliferative response to mitogens and antigens [36]. A
similar increase in helper/suppressor ratio after rHuEPO admin-
istration to hemodialysis patients was reported by Pfaffl et al
[25]. Simultaneously, in 7 of 11 patients tested, a transitory
increase in their response to recall antigens was noted, consis-
tent with improved cell mediated immune responsiveness. At
first glance our results may appear to conflict with those of
Grimm et al [26], who demonstrated a decrease in both humoral
sensitization and nonspecific cell-mediated immunity after ad-
ministration of rHuEPO to five highly sensitized adolescents on
dialysis. In this regard it should be emphasized that our study
was performed in older and unsensitized patients who likely
have a completely different immune-responder status.
Since lymphocyte subpopulations can change markedly over
time, blood samples were always taken at the same time of the
day and before dialysis, to avoid any influence of circadian
rhythms [37, 38] or dialysis procedure [39, 40] on lymphocyte
subsets. Secondly, the mean value for any given prevaccination
immune parameter did not change significantly for either
rHuEPO treated or uremic controls on repeat determinations.
Therefore, the observed changes in lymphocyte subsets do not
represent individual variations but can be assigned a causal
relationship with rHuEPO administration. The question of
whether the phenotypic changes in the T lymphocyte popula-
tion observed in patients receiving rHuEPO were a direct effect
of the drug itself or resulted from concomitant avoidance of
blood transfusion was subsequently addressed. In view of the
well known effect of blood transfusion on the immune system
[41—44] it was important to link differences in lymphocyte
subpopulations of rHuEPO treated and untreated subjects with
their transfusion history. In agreement with previous studies
[13, 14], a negative correlation was found between number of
prevaccination transfusions and total number of T cells and T
helper cells when the entire study population was considered.
Therefore, the decrease in absolute number of T cells and
helper lymphocytes in rHuEPO treated subjects may reflect a
higher transfusion burden rather than an effect of rHuEPO
itself. On the other hand, blood transfusion has been shown to
generate T suppressor cells and to decrease the helper/suppres-
sor ratio for at least two weeks [45—47]. Hence, the lower
transfusion requirements since the start of rHuEPO and during
the vaccination period may have favored the helper/suppressor
balance in the rHuEPO treated group by reducing suppressor
cell generation. Transfusion avoidance alone may not be the
sole mechanism by which treatment with rHuEPO improves
immune reactivity. Indeed, the reduced T helper population
noted in the nonresponder group could not be attributed to a
higher transfusion burden since the number of previous blood
transfusions and ferritin levels were comparable in high and
nonresponders, the only difference being a near absence of
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transfusion during the vaccination period in the high responder
group. Furthermore, variables such as age, gender, duration of
dialysis, blood urea nitrogen, serum creatinine and previous
blood transfusions had little effect on the intensity of antibody
response. On the contrary, the influence of treatment with
rHuEPO and high helper/suppressor ratio on antibody concen-
tration was still significant when discriminant multivariate anal-
ysis was performed. All together, this would suggest that the
contribution of transfusion avoidance alone to the improved
serological response after hepatitis B vaccination may be less
important than rHuEPO therapy itself. Evidence of direct
effects of rHuEPO upon T and B lymphocytes is now emerging
rapidly. Schaefer, Paczek and Heidland [48] demonstrated
enhanced basal and mitogen stimulated immunoglobulin pro-
duction by cultured peripheral blood mononuclear cells of
dialysis patients after eight weeks of rHuEPO administration.
The stimulation of B lymphocytes was not mediated by T helper
cells or monocytes, suggesting a direct interaction between B
lymphocytes and rHuEPO. A direct stimulatory effect of
rHuEPO upon B lymphocytes can therefore not be excluded,
despite comparable absolute numbers of B lymphocytes in
patients receiving rHuEPO, uremic controls, nonresponders
and high responders. Finally, Kalechman et al [49] showed
evidence of increased production of cytokines (interleukin-2) by
peripheral blood mononuclear cells of hemodialysis patients as
early as eight weeks after the start of treatment with rHuEPO,
suggesting an interaction between T lymphocytes and rHuEPO
as well. In conclusion, under treatment with rHuEPO, the
impaired immune reactivity of dialysis patients can improve.
This is illustrated by enhanced antibody production after hep-
atitis B vaccination. There are associated phenotypic changes
in the T lymphocyte subsets suggesting an up-regulation of the
T cell population. The improved serological response may not
be accounted for by a concomitant reduction of blood transfu-
sion during rHuEPO administration alone, raising the possibil-
ity of a direct effect of the drug itself. Although this analysis was
performed following hepatitis B vaccination, there is no reason
to anticipate that the more satisfying antibody response could
not be extended to other vaccinations as well.
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